.jpg)
Alethium holds a Small Business Innovation Research Phase I award from the Advanced Research Projects Agency for Health. The study conducted under it falls within the most heavily protected category of human subjects research: pediatric participants who cannot consent, no research sites, and technology that operates in settings the study does not control.
Studies of this class are uncommon because they are difficult to design and more difficult to clear. A federal sponsor applies human subjects scrutiny most commercial protocols never encounter, and every protection that a site, a verbal participant, or a controlled setting would ordinarily supply must be rebuilt and justified in the protocol.
The study is ours. What follows is how each protection was rebuilt.
No research sites
Minimally verbal children do not travel well to research sites, and the sites are rarely near them. The study is home-based: visits occur in the participant's home, in another location the family chooses, or by video. There are no research sites, no site initiation, and no site monitoring, because there are no sites. Every element of oversight a site would normally carry had to be rebuilt around the family.
A waiver of assent, justified rather than asserted
Eligibility requires participants to be minimally verbal or to rely on augmentative communication as their primary mode. That is precisely the characteristic that prevents conventional assent. The protocol submits that the capability of participants, considered as a group, is so limited that they cannot reasonably be consulted, and the waiver was granted on that basis for the full age range of 4 to 18.
A waiver is not a removal of protection. It obliges the design to replace what assent would have provided.
Refusal recognized behaviorally
A participant who cannot say no can still refuse. The protocol treats sustained distress, refusal, or withdrawal-equivalent behavior during use as withdrawal of participation, resulting in immediate cessation. Caregivers are trained at the first visit to recognize those signs and act on them, and they keep a plain-language reporting card describing exactly when to call and how urgently.
This is the substantive substitute for assent. It only works if the people present every day know what they are looking for.
Safety oversight without a site
In a site-based study, a coordinator notices when something is wrong. In a home-based study nobody is watching, so oversight has to be scheduled. A clinician contacts the caregiver mid-week, by whichever channel the family prefers, with defined escalation criteria and a documented response window when contact is not returned. The contact is risk management rather than data collection, and it is logged as such.
Bystanders protected by architecture
Research technology that travels with a participant will be present around people who never joined the study. Household members can be notified in advance, and are. Outside the home, notification is not practicable, so the protection cannot be a notice nobody reads.
The design's answer is retention. Nothing about a bystander is kept: processing happens on the device, nothing is stored, and no persistent record of anyone's speech exists to be protected in the first place. The protection is architectural rather than procedural, which is what makes it hold in settings the study cannot control.
A conflict disclosed and structured around
The principal investigator is also the chief executive of the company that developed the technology under study. Rather than leave that to disclosure alone, the protocol structures around it: a sole consenting investigator working from a written script, recruitment performed by a consultant compensated on effort rather than enrollment, no recruitment from existing commercial relationships, direct identifiers held separately from study data, and clinical authority on participant safety vested in the study clinician, which the investigator implements and cannot override.
Cleared at the agency
ARPA-H cleared the study through the agency's human subjects research oversight review. Solutions IRB approved it under Alethium's Federalwide Assurance with the Office for Human Research Protections, with determinations covering minimal risk, one-parent permission, the assent waiver, and the conflict-of-interest mitigation plan.
Designed. Reviewed. Cleared.
The studies worth conducting are often the ones that are most difficult to design.
Note: This project has been funded in whole or in part with Federal funds from the Advanced Research Projects Agency for Health (ARPA-H) under Contract No. 140D0426C0028. Phase I is financed with 100 percent Federal funds totaling $597,951. No nongovernmental funds finance this phase.
